Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is an innovative biotechnology company with a promising drug candidate, PIKTOR, in development for endometrial and breast cancer. While the company has shown promising data and a strong cash balance, it also faces competition in the market from other drugs targeting the same pathways. However, PIKTOR's multi-way inhibition and potential advantages make it an attractive investment opportunity for those with a positive outlook on the company's potential success.

Bears say

Faeth Therapeutics is heavily reliant on the success of its PIKTOR program, which is still in the clinical stage and has not yet received approval from regulatory authorities. The company faces competition from well-established players in the industry and while serabelisib may have potential, its ultimate success is uncertain. The company's reliance on a single program and uncertainties in the competitive landscape pose significant financial risk and make the stock a risky investment with a negative outlook.

FTH has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Buy based on their latest research and market trends.

According to 7 analysts, FTH has a Buy consensus rating as of Aug 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.